Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 3 4Phase 1 4Phase NA 1Phase 1/2 1

Status

Completed 3Active not recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 2Tumor-Agnostic 1Other solid neoplasm 1

Conditions

Solid Tumors 1Metastatic Pancreatic Adenocarcinoma 1CLDN18.2-positive Gastric Adenocarcinoma 1Adenocarcinoma 1

Interventions

Cyclophosphamide 624pembrolizumab 500Paclitaxel 456Gemcitabine 438Carboplatin 435Cisplatin 418Radiotherapy 380fludarabine 365Nivolumab 340Docetaxel 277Bevacizumab 276Irinotecan 257Magnetic Resonance Spectroscopy 242Fluorouracil 228Dexamethasone 225Specimen Handling 221Capecitabine 218Rituximab 205Cytarabine 201Oxaliplatin 200Ipilimumab 199Temozolomide 197Biopsy 196fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 173Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Interventional × zolbetuximab × Clear all
NCT06396091 2025-11-13

A Study of Zolbetuximab With Chemotherapy in Adults With Pancreatic Cancer

Astellas Pharma Inc

Phase 1 Active not recruiting
12 enrolled
Gastrointestinal

Metastatic Pancreatic Adenocarcinoma

NCT00909025 2024-11-21

Safety and Tolerability Study of Claudiximab in Patients With Advanced Gastroesophageal Cancer

Astellas Pharma Inc

Phase 1 Completed
15 enrolled
Other solid neoplasm

Solid Tumors

NCT04086758 2024-11-20

A Pharmacokinetic Study of Zolbetuximab (IMAB362) in Chinese Subjects With Locally Advanced Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma

Astellas Pharma Inc

Phase 1 Completed
12 enrolled
Tumor-Agnostic

Adenocarcinoma

NCT01671774 2024-11-14

PILOT

Astellas Pharma Inc

Phase 1 Completed
29 enrolled
Gastrointestinal

CLDN18.2-positive Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡